Emergent BioSolutions Receives Health Canada Approval of BioThrax® (Anthrax Vaccine Adsorbed)
GAITHERSBURG, Md. , Dec. 17, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that Health Canada has approved the company’s New Drug Submission (NDS) for its...
Emergent BioSolutions and Valneva Report Positive Phase 1 Results for Their Vaccine Candidate Against the Zika Virus
GAITHERSBURG, Md. and SAINT-HERBLAIN, France , Nov. 19, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) and Valneva SE (VLA) today announced positive interim results for the...
Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months of 2018
Q3 2018 performance in line with guidance Revises full year 2018 financial forecast to reflect anticipated strong full year organic business performance, expected at the higher end of the previous...
Emergent BioSolutions to Offer All Public Libraries and YMCAs in the U.S. Free Opioid Awareness Education and NARCAN® (naloxone HCl) Nasal Spray
New initiatives make free doses and educational materials available to thousands of public libraries & YMCAs in the U.S. GAITHERSBURG, Md. , Oct. 24, 2018 (GLOBE NEWSWIRE) — Emergent...
Emergent BioSolutions Completes Acquisition of Adapt Pharma and Flagship Product Narcan® (Naloxone HCI) Nasal Spray
GAITHERSBURG, Md. , Oct. 15, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed its acquisition of Adapt Pharma and its flagship product NARCAN...
Emergent BioSolutions to Release Third Quarter 2018 Financial Results and Conduct a Conference Call on November 1, 2018
GAITHERSBURG, Md. , Oct. 11, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 1, 2018 at 5:00 pm (Eastern Time) to discuss the...
Emergent BioSolutions Completes Acquisition of Specialty Vaccines Company PaxVax
GAITHERSBURG, Md. , Oct. 04, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of PaxVax, a company focused on developing,...
Emergent BioSolutions Joins Effort to Combat National Public Health Threat From Opioid Overdose Through Acquisition of Adapt Pharma and Its Flagship Product NARCAN® (naloxone HCl) Nasal Spray
Acquisition advances Emergent’s mission, vision and strategic growth plan by: Diversifying and expanding company’s presence within the public health threats market to respond to the opioid...
Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences
GAITHERSBURG, Md. , Aug. 17, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the...
CEPI Awards Contract Worth up to $36 million to Profectus BioSciences and Emergent BioSolutions to Develop Lassa Virus Vaccine
OSLO, Norway, BALTIMORE and GAITHERSBURG, Md., Aug. 16, 2018 (GLOBE NEWSWIRE) — CEPI (the Coalition for Epidemic Preparedness Innovations ) today announced a new collaboration with Profectus...
Emergent BioSolutions to Acquire Specialty Vaccines Company PaxVax
Adds two revenue-generating FDA -licensed vaccines that protect against cholera and typhoid fever, both with dual-market potential Broadens development pipeline with an adenovirus 4/7 vaccine funded...
Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months of 2018
Q2 2018 total revenues of $220 million , net income of $50 million Reaffirms full year 2018 financial forecast and operational goals GAITHERSBURG, Md. , Aug. 02, 2018 (GLOBE NEWSWIRE) —...